Postvaccination Multisystem Inflammatory Syndrome in Adult with No Evidence of Prior SARS-CoV-2 Infection

Abstract

Ten days after receiving the first dose of coronavirus disease vaccine, a 22-year-old woman in South Korea experienced myocarditis, myopathy, pericarditis, and gastroenteritis; rash subsequently developed. There was no evidence of prior infection with severe acute respiratory syndrome coronavirus 2. The diagnosis was multisystem inflammatory syndrome resulting from coronavirus disease vaccination.

Keywords: 2019 novel coronavirus disease; COVID-19; ChAdOx1 nCoV-19 vaccine; MIS-A; SARS-CoV-2; anti-S receptor-binding protein antibody; atrial fibrillation; coronavirus disease; multisystem inflammatory syndrome; myopathy; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine-related adverse events; viruses; zoonoses.

Figure 1

Clinical course of illness in adult with postvaccination multisystem inflammatory syndrome and no evidence of prior SARS-CoV-2 infection, South Korea. A) Signs/symptoms according to the day of hospitalization and the days since vaccination. B) Patient’s maximum body temperature and anti-inflammatory therapy according to the day of hospitalization. Dexa, dexamethasone; IVIG, intravenous immunoglobulin; MPD, methylprednisolone.

Figure 2

Colloidal gold qualitative immunoassay for antibodies against severe acute respiratory syndrome coronavirus 2, South Korea. A) Nucleocapsid protein conjugate; B) spike receptor-binding domain conjugate. The positive control serum contains antinucleocapsid IgG and anti–spike protein receptor-binding IgM. C, control.